References
- Vakifahmetoglu-Norberg H, Ouchida AT, Norberg E. The role of mitochondria in metabolism and cell death. Biochem Biophys Res Commun 2017; 482:426. DOI: 10.1016/j.bbrc.2016.11.088
- West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol 2011; 11:389. DOI: 10.1038/nri2975
- Halliwell B.The role of oxygen radicals in human disease, with particuar reference to the vascular system . Haemostasis 1993;23(Suppl 1 ):118-126. DOI: 10.1159/000216921
- Ichikawa I, Kiyama S, Yoshioka T. Renal antioxidant enzymes: their regulation and function. Kidney In 1994; 45:1–9. DOI: 10.1038/ki.1994.1
- Klemm A, Voigt C, Friedrich M et al. Determination of erythrocyte antioxidant capacity in haemodialysis patients using electron paramagnetic resonance. Nephrol Dial Transplant 2001;16: 2166–2171, DOI: 10.1093/ndt/16.11.2166
- Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 1999;31:261–272. DOI: 10.1080/1071576990 0300841.
- Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species-reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000; 20:1716–1723. DOI: 10.1161/01.atv. 20.7.1716
- Griendling KK, Sorescu D, Ushio‐Fukai M. NAD(P)H oxidase—role in cardiovascular biology and disease. Circ Res 2000; 86:494–501. DOI: 10.1161/01.res.86.5.494.
- Vásquez‐Vivar J, Kalyanaraman B. Generation of superoxide from nitric oxide synthase. FEBS Letters 2000;481:305–306. DOI: 10.1016/s0014-5793(00) 02001-9.
- Böger RH, Böde‐Boger SM, Phivthong‐ngam L et al. Dietary L‐arginine and α‐tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis 1998;141:31–43.DOI: 10.1016/s0021-9150(98)00145-2.
- Heitzer T, Brockhoff C, Mayer B et al. Tetrahydrobiopterin improves endothelium‐ dependent vasodilation in chronic smokers—evidence for a dysfunctional nitric oxide synthase. Circ Res 2000;86:E36–E41. DOI.org/10.1161/01.RES.86.2.e36
- Dobashi K, Ghosh B, Orak JK, Singh I, Singh AK. Kidney ischemia‐reperfusion: modulation of antioxidant defenses. Mol Cell Biochem 2000; 205:1–11
- Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000; 28: 1387–1404
- Hannken T, Schroeder R, Zahner G, Stahl RAK, Wolf G. Reactive oxygen species stimulate p44/42 mitogen‐ activated protein kinase and induce p27Kip1: role in angiotensin II‐mediated hypertrophy of proximal tubular cells.J Am Soc Nephrol 2000; 11: 1387–1397
- Berdeaux O, Scruel O, Durand T. Isoprostanes, biomarkers of lipid peroxidation in humans. Part 2: quantification methods. Pathol Biol. 2005;53:356–63.
- Grzebyk E, Piwowar A. Inhibitory actions of selected natural substances on formation of advanced glycation end products and advanced oxidation protein products. Complement Altern Med. 2016;16:38–41
- Butkowski EG, Al-Aubaidy HA, Jelinek HF. Interaction of homocysteine, glutathione and 8-hydroxy-2’-deoxyguanosine in metabolic syndrome progression. Clin Biochem. 2016;15:22–36.
- Haleng J, Pincemail J, Defraigne JO, Charlier C, Chapelle JP. Le stress oxydant. Rev Med Liege. 2007;62:628–38.
- Čolak E, Ignjatović S, Radosavljević A, Žorić L. The association of enzymatic and non-enzymatic antioxidant defense parameters with inflammatory markers in patients with exudative form of age-related macular degeneration. J Clin Biochem Nutr. 2017;60:100–7.
- Bover J, Evenepoel P, Ureña-Torres P, et al. Pro: cardiovascular calcifications are clinically relevant. Nephrol Dial Transplant 2015; 30:345.
- Zoccali C, London G. Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transplant 2015; 30:352.
- Tabas I, Bornfeldt KE. Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Circ Res 2016; 118:653.
- Watanabe S, Fujii H, Kono K, et al. Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus. Sci Rep 2020; 10:20708.
- Wei R, Enaka M, Muragaki Y. Activation of KEAP1/NRF2/P62 signaling alleviates high phosphate-induced calcification of vascular smooth muscle cells by suppressing reactive oxygen species production. Sci Rep 2019; 9:10366.
- Witko-Sarsat V, Drüeke T, Descamps-Latscha B, Canteloup S. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524–32.
- Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18:4266–88.
- Schmitz G, Herr AS, Rothe G. T-lymphocytes and monocytes in atherogenesis. Herz. 1998;23:168–77.
- Ikeda U, Takahashi M, Shimada K. Monocyteendothelial cell interaction in atherogenesis and thrombosis. Clin Cardiol. 1998;21:11–4.
- Descamps-Latscha B, Witko-Sarsat V. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2005;45:39–47.
- Weiner DE, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis. 2006;48:392–401.
- Migdal C, Serres M. Especes reactives de l’oxygene et stress oxydant. Med Sci. 2011;27:405–12.
- Maziere C, Gomila C, Maziere JC. Oxidized low-density lipoprotein increases osteopontin expression by generation of oxidative stress. Free Radic Biol Med. 2010;48:1382–7.
- Beaudeux JL, Peynet J, Bonnefont-Rousselot D, et al. Cellular sources of reactive oxygen and nitrogen species. Roles in signal transcription pathways. Ann Pharm Fr. 2006;64:373–81.
- Bogna G, Dorota F, Magdalena B, et al. Advanced oxidation protein products and carbonylated proteins as biomarkers of oxidative stress in selected atherosclerosis-mediated diseases. Biomed Res Int. 2017;20:487–97.
- Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res. 2009;82:9–20.
- Beaudeux JL, Dellatre J, Therond P, Bonnefont-Rousselot D, Legrand G, Peynet J. Le stress oxydant, composante physiopathologique de l’athérosclérose. Immuno-analyse Biologie Spécialisée. 2006;21:144–50.
- Choi B, Kang KS, Kwak MK. Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules. 2014;19:12727–59.
- Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expressionof interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelialcells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002;195:245–57.
- Shen G, Jing L. Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease. Chron Dis Transl Med. 2017;3:89–94
- Meier P, Spertini F, Blanc E, Burnier M. Oxidized low density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement. Am Soc Nephrol. 2007;18:331–42.
- Kita T, Kume N, Minami M, et al. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci. 2001;947:199–205.
- Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115:610.DOI: 10.1172/JCI23056
- Scindia Y, Dey P, Thirunagari A, et al. Hepcidin Mitigates Renal Ischemia-Reperfusion Injury by Modulating Systemic Iron Homeostasis. J Am Soc Nephrol 2015; 26:2800. DOI: 10.1681/ASN.2014101037.
- Klahr S. Oxygen radicals and renal diseases.Miner Electrolyte Metab1997; 23:140–143.
- Witko Sarsat V, Friedlander M, Capeillere Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304–1313
- Cristol JP, Bosc JY, Badiou S et al. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial transplant 1997; 12: 2312–2317
- Beutler E, Dale GL. Erythrocyte glutathione. In: Dolphin D, Avramovic O, Poulson R, eds. Glutathione: Biochemical and Medical Aspects. Part B. John Wiley & Sons, New York, 1989; 291
- Biasioli S, Schiavon R, De Fanti E, Cavalcanti G, Giavarina D. The role of erythrocytes in the deperoxidative processes in people on hemodialysis. ASAIO J 1996; 42: M890–M894
- Costagliola C, Romano L, Sorice P, Di‐Benedetto A. Anemia and chronic renal failure: the possible role of the oxidative state of glutathione. Nephron1989; 52: 11–14
- Ceballos‐Picot I, Witko‐Sarsat V, Merad‐Boudia M et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol red 1996; 21:845–853
- Canestrari F, Galli F, Giorgini A et al. Erythrocyte redox state in uremic anemia: effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994; 91: 187–193
- Chu P, Cadley M, Bellingham AJ. Red cell metabolism in renal failure—the effect of dialysis. Clin Lab Haemat 1985; 7: 1–5
- Yawata Y, Jacob HS. Abnormal red cell metabolism in patients with chronic uraemia—nature of the defect and its persistence despite adequate hemodialysis. Blood 1975; 45: 231–239
- Ansley DM, Sun J, Visser WA et al. High dose propofol enhances red cell antioxidant capacity during CPB in humans.Can J Anaesth 1999; 46: 641–648
- Repetto MG, Reides CG, Evelson P, Kohan S, de-Lustig ES, Llesuy SF. Peripheral markers of oxidative stress in probable Alzheimer patients.Eur J Clin Invest 1999; 29:643–649
- Maples KR, Kennedy CH, Jordan SJ, Mason RP. In vivo thiyl free radical formation from hemoglobin following administration of hydroperoxides. Arch Biochem Biophys 1990; 277: 402–409
- Gwozdzinski K, Janicka M, Brzeszczynska J, Luciak M. Changes in red blood cell membrane structure in patients with chronic renal failure.Acta Biochim Pol 1997;44 :99–107.